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Abstract 
Title: Is opioid substitution treatment beneficial if injecting behaviour continues?  
Background 
Opioid substitution treatment (OST) is recognised as an effective treatment for opioid 
dependence. Still, a subgroup of OST users continues to inject drugs. This study examines 
health risks and criminal activity in a population of needle exchange programme (NEP) 
participants by comparing those identified as current OST users to i) those identified as 
former OST users and ii) those with no OST experience.  
Methods 
This was a semi-annual cross-sectional study conducted from 2002 to 2011. NEP participants 
were interviewed in Oslo, Norway (n=1,760); 341 were identified as current OST users, 356 
as former OST users and 1,063 had no OST experience. The associations between OST status 
and health risk and criminal activity were assessed through univariate and multiple logistic 
regression analyses. 
Results 
Among NEP participants, those currently in OST had fewer non-fatal overdoses (OR=0.5 
[95% CI 0.3, 0.9]) compared to former OST users and those never in OST. Additionally, they 
were less likely to have injected frequently (OR=0.4 [95% CI 0.3, 06]), to have used heroin 
daily or almost daily (OR=0.3 [95% CI 0.2, 0.4]), and to have committed theft (OR=0.6 [95% 
CI 0.4, 1.0]) and engaged in drug dealing (OR=0.7 [95% CI 0.5, 0.9]) in the past month. 
Overall, there was a high level of polysubstance use and no group differences on this measure.   
Conclusions  
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NEP participants who are currently in OST have substantially reduced health risks and 
criminal activity than other NEP participants. The high level of polysubstance use 
nevertheless poses a public health challenge. 
Key words: Opioid substitution treatment, drug user, injecting drug user, needle-exchange 
programmes, overdose, crime 
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1. INTRODUCTION 
Some injecting drug users (IDU) in opioid substitution treatment (OST) inject while in 
treatment (Judson et al., 2010; Li et al., 2012), and consequently, continue to use needle 
exchange programmes (NEP) services (Gervasoni et al., 2012; Kerr et al., 2005). Continued 
drug use is cited as evidence of the failure of OST (Gyngell, 2011), and it is one of the 
reasons why the UK government, since 2010, has moved towards a drug strategy that 
emphasises rehabilitation with the aim of abstinence rather than OST (UK Government, 
2010). This move has caused considerable debate around the benefits and cost effectiveness 
of OST (O'Hara, 2012). A rise in methadone-related deaths in Scotland in 2012 (National 
Statistics Scotland, 2012) has sparked the debate further (Christie, 2012; Spence, 2012). 
OST has been found to benefit both IDUs and the general population by reducing health risks 
associated with injection drug use and criminal activity (Ball and Ross, 1991; MacArthur et 
al., 2012). There are documented effects on the reduction of morbidity and mortality risk also 
among those who continue to use drugs while in treatment (Gervasoni et al., 2012; Kerr et al., 
2005; Kidorf et al., 2011; Millson et al., 2007). Many of these studies have recruited subjects 
that are willing and able to participate in specific interventions and follow-up evaluations 
(Kidorf et al., 2011; Van Ameijden et al., 1999). They may therefore not have included those 
who are unable to attend follow-up evaluations.  
Thus, there is a need for a comparative assessment of health risks and criminal activity among 
OST users who continue to inject drugs. One question of substantial political interest is 
whether OST users who continue to inject drugs benefit sufficiently from treatment to defend 
the cost of treatment provision. This study examines health risks and criminal activity in a 
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population of NEP participants by comparing those identified as current OST users to i) those 
identified as former OST users and ii) those with no OST experience.  
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2. METHODS 
2.1 A brief introduction to the Norwegian NEP and OST programme 
Norway has approximately 5 million inhabitants and about 600,000 live in the capital, Oslo 
(Statistics Norway, 2012). The majority of heroin and amphetamine users inject and there is 
an estimated 8,700 to 12,300 IDUs (predominantly opioids), where approximately 3,000 of 
them live in the capital (Bretteville-Jensen and Amundsen, 2009). NEP was established in 
1988, and it is part of the low threshold services provided by the city of Oslo. Annually, 
between 1.2 and 2 million syringes are distributed in Oslo (Norwegian Institute for Alcohol 
and Drug Research, 2012). The majority of needles and syringes are distributed from the only 
NEP facility in the city, but clean needles and syringes are also available from other low 
threshold services such as shelters, street clinics and the injection room. Over the study 
period, the mean annual number of individual visits to the NEP facility was 96,000. 
OST became nationally available in Norway in 1998, as part of public health care services. In 
Norway, OST is only available through a public specialised health care programme (Waal, 
2007). At the end of 2012, there were 6,640 OST users nationally (Waal et al., 2012). 
Treatment initiation is the responsibility of a regional OST centre, but after the initial phase, a 
GP may act as the prescribing doctor under supervision by the centre (Gjersing et al., 2011). 
Buprenorphine has been available since 2001, and in 2011 49% of OST patients were 
prescribed buprenorphine (Waal et al., 2012). The average dose was 103 mg for methadone 
and 18 mg for buprenorphine in 2011 (op.cit). 
2.2 Design 
Data was drawn from a semi-annual cross-sectional study conducted outdoors, outside the 
only NEP facility in the city centre of Oslo. The study has been conducted by The Norwegian 
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Institute for Alcohol and Drug Research since 1993 and interview sessions are held each year 
in March and September. The study operates independently from the NEP facility, but 
management and staff are familiar with the purpose of the study and they are notified in 
advance of which days data will be collected. Relevant variables were included into the study 
instrument from 2002, thus this study used data collected between 2002 and 2011.  
2.3 Participants and recruitment 
Participants collected injecting equipment from the NEP facility before they were approached. 
The inclusion criterion was to have injected at least once in the previous four weeks. 
However, since stimulant drug users who do not use heroin are not eligible for OST treatment, 
only those with heroin experience were included.  
Researchers and trained research assistants from The Norwegian Institute for Alcohol and 
Drug Research recruit and interview participants during the facility’s opening hours two or 
three weeknights within a month. The interview takes approximately 15 minutes to complete, 
and is conducted out of earshot from others. The respondents do not receive any monetary 
incentive for participation. Those who are too intoxicated are not approached. Among those 
who decline to participate, the most common reasons for refusal are that they do not have time 
or are experiencing withdrawal symptoms. No names or other personal information were 
collected. Those who were interviewed within the same month were excluded.  
The study sample was divided into three groups based on their OST status at the time of the 
interview. The three groups were “OST users” who were currently in OST, “former OST 
users” who had been OST users in the past and “never OST users” who did not have any OST 
experience. Since 2002, there has been a steady increase in subjects who report that they are 
currently in OST or have been in the past. 
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2.4 Measures 
The study instrument comprised detailed questions of participants’ nationality, education, 
current living situation, sources of income (including illegal activities), type of substances 
used, number of injections and amount of drug used in the previous four weeks, and non-fatal 
overdose experiences in the previous four weeks. The questionnaire is described in more 
details elsewhere (Bretteville-Jensen and Skretting, 2010). Since 2002, respondents have been 
asked if they are currently in OST. If they are not currently in OST, they are asked if they 
have previously been in OST.  
Non-fatal overdoses, having injected 100 times or more, daily or almost daily heroin use, and 
to have used more than one substance in the past month were chosen as outcome measures 
and indicators for health risks. In the total sample the mean number of injections was 99.8 in 
the past month, and thus this was set as the cut off for the variable “Injected 100 times or 
more”. This variable reflected the total number of injections from heroin, amphetamine, 
cocaine, morphine and injections of all types of pills including benzodiazepines. Almost daily 
heroin use means to have used heroin four to six days a week. Theft and drug dealing 
committed in the past month were chosen as outcome measures and indicators for criminal 
activity. 
2.5 Ethics 
The information collected in this study is anonymous and non-identifiable (no names, date of 
birth, addresses, names of locations, occupation, etc. are collected). Since no personal 
information was collected, approval by the Norwegian ethics committee was not required.  
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2.6 Data analyses 
Descriptive statistics and logistic regression analyses were completed using Stata version 
12.1. In the univariate and multiple logistic regression analyses odds ratios (OR) with 95% 
confidence intervals (95% CI) were estimated and the differences between NEP users 
currently in OST and the two other groups (former and never OST users) were assessed.  
In the multiple logistic regression analyses both former and never OST users were included as 
the reference group. The variables used in the multiple regression models were based upon 
known risk factors for overdoses, injection frequency, substance use and criminal activity 
available in the data. These variables were age, gender, length of injecting career, 
homelessness and shelter use (Bird and Robertson, 2007, Hickman et al., 2007, Loyd-Smith et 
al., 2008, Nordentoft et al., 2003; Ødegård et al., 2007). Length of injecting career is only 
known as a risk factor for overdoses (Ødegård et al., 2007), and it was therefore not used in 
the other multiple regression models. Furthermore, in all multiple regression models the time 
effect was adjusted for using one year dummy variables, and possible cohort effects were 
adjusted for using dummy variables for birth decades. In the tables for the multiple logistic 
regression models, the unadjusted estimates are also presented. 
Logistic regression analysis requires observations to be independent. In this study, some 
subjects may have been interviewed more than once during the study period since all subjects 
were anonymous. It is also possible that an individual could be in more than one group as the 
divisions into groups were based on OST status at the time of interview. To address this 
potential bias, we combined a set of background variables to separate individuals from one 
interview session to another and deleted possible duplicates prior to running the models. The 
identifying variables were “gender”, “age”, “educational level”, “age at first injection”, “type 
of drug at first injection”, “how heroin was used the first time” and “age at first heroin 
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smoking”1. From a total number of 1,827 interviews, 67 (4%) cases were removed in the 
preferred model. In case this procedure did not remove all duplicates, it can further be 
formally shown that given a relatively low ratio between the number of observations and the 
population size (which is the case here), estimation results will not be biased
2
.  
  
                                                 
1
 Please see Appendix 1 for additional analyses using different combinations of variables. 
2
 Please see Appendix 2 for more details. 
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3. RESULTS 
3.1 Characteristics of the sample 
In total, 1,760 individuals were interviewed outside the NEP facility between 2002 and 2011; 
341 participants were identified as current OST users, 356 as former OST users and 1,063 had 
no OST experience. The NEP participants currently in OST were the same age as former OST 
users (37.3 years, SD 7.8 and 37.6 years, SD 8.8, respectively), but two years older than those 
never in OST (34.6 years, SD 9.1). Those currently in OST were approximately the same age 
as former OST users when they first injected (18.4 years, SD 5.5 vs. 18.9 years, SD 5.9), 
whereas they were two years younger than those never in OST (20.3 years, SD 6.8).  
The majority (n=1,206) of the full sample were men and there were no gender differences 
across groups (Table 1). Similarly, two-thirds (n=1,148) had completed more than the 
mandatory years of education, which are the years children are expected by law to attend 
school. There were no group differences in educational attainment. Compared to the two other 
groups, fewer NEP participants currently in OST were homeless or shelter users at the time of 
the interview (OR=0.4 [95% CI 0.3, 0.5]). 
3.2 Health risks 
Table 1 shows that NEP participants currently in OST had less health risks compared to 
former OST users and those never in OST. Fewer (4%) reported non-fatal overdoses in the 
past month (OR=0.4 [95% CI 0.2, 0.8]). A significantly smaller proportion (27%) had injected 
100 times or more in the past month compared to former OST users (56%) and those never in 
OST (46%) (OR=0.4 [95% CI 0.3, 0.5]). They had on average injected 66.1 times (SD 71.0) 
in the past month, compared to former OST users who had injected 120.2 times (SD 81.9) and 
those never in OST 103.7 times [SD 74.1]. Furthermore, fewer (39%) had injected heroin 
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daily or almost daily in the past month (OR=0.3 [95% CI 0.2, 0.3]), which was half the 
proportion of former OST users (82%) and also less than those who had never been in OST 
(67%).  
Table 1 also shows that the vast majority of NEP participants in OST (97%) had used more 
than one substance in the previous month and there were no significant group differences 
(OR=0.8 [95% CI 0.4, 1.7]). All groups had on average used four different substances (SD 
1.3) in the past month. A smaller proportion of those in OST (27%) had injected amphetamine 
daily or almost daily compared former  OST users (32%) and those never in OST (34%) 
(OR=0.7 [95% CI 0.6, 1.0]). In this study, there were no differences in other substances used, 
except that a slightly higher proportion of those currently in OST (39%) had used cannabis 
daily or almost daily compared to 33% of former OST users and 31% of those never in OST 
(OR=1.4 [95% CI 1.1, 1.8]). 
3.3 Crime 
A significantly smaller proportion of NEP participants currently in OST had committed theft 
(7%) (OR=0.5 [95% CI 0.3, 0.8]), and engaged in drug dealing (29%) in the past month 
(OR=0.6 [95% CI 0.5, 0.8]) (Table1) compared to former OST users and those never in OST.  
3.4 Multiple logistic regression analysis 
Table 2 shows the unadjusted and adjusted ORs for the health risk indicators. The table shows 
that NEP participants currently in OST were 50% less likely to have experienced one or more 
non-fatal overdoses in the past month compared to the two other groups in unadjusted and 
adjusted analysis (OR=0.5 [95% CI 0.3,0.9]). Those currently in OST were also 60% less 
likely to have injected 100 times or more in the past month compared to the two other groups 
(OR=0.4 [95% CI 0.3,0.6]). Furthermore, those currently in OST were 70% less likely to have 
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used heroin daily or almost daily in the past month in adjusted analysis (OR=0.3 [95% CI 0.2, 
0.4]). There were no significant differences between groups in regards to having used more 
than one substance in the past month (OR=1.0 [95% CI 0.4, 2.2]).  
Table 3 shows the unadjusted and adjusted ORs for theft and drug dealing over the previous 
four weeks. NEP users currently in OST were 40% less likely to have used theft as an income 
source compared to the two other groups at a 10% significance level (OR=0.6 [0.4, 1.0]). 
They were also 30% less likely to have used drug dealing as an income source compared to 
the two other groups, including adjustment for other factors (OR=0.7 [95% CI 0.5, 0.9]). 
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4. DISCUSSION 
NEP participants who are currently in OST appear to have fewer health risks and impose less 
harm to the general population through criminal activity than former OST users and those 
never in OST. Those currently in OST reported fewer non-fatal overdoses, fewer injections, 
fewer daily or almost daily injections of heroin, and fewer had engaged in theft and drug 
dealing in the past month compared to the other NEP participants. The sustained high level of 
polysubstance use nevertheless poses a public health challenge. 
Non-fatal overdoses increase the risk of medical complications such as peripheral neuropathy, 
chest infections and temporary paralysis of limbs (Darke and Hall, 2003a; Warner-Smith et 
al., 2002). Furthermore, it has been found that the majority of those who die from overdoses 
have previously experienced several non-fatal overdoses, and it is suggested that non-fatal 
overdoses may increase the risk for future overdoses (Darke et al., 2003b). Heroin injected in 
combination with other substances is one of the most common toxicological causes of 
overdoses (Kerr et al., 2007). In this study, almost all NEP participants who were currently in 
OST were polysubstance users, all had injected in the past month and 39% had injected heroin 
daily or almost daily. Despite the presence of these risk factors, fewer of those currently in 
OST reported non-fatal overdoses in the month leading up to the interview compared to the 
other NEP participants. This suggests that OST contributes to reduced health risks despite the 
high prevalence of risky drug use behaviours. Furthermore, OST was associated with less 
heroin use and this is likely another reason why fewer of those who were currently in OST 
reported non-fatal overdoses.  
Injections are not only associated with risk of fatal and non-fatal overdoses, they are also 
associated with HIV, hepatitis, cutaneous injection-related infections and venous disease 
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(Lloyd-Smith et al., 2008; Pieper et al., 2009). Fewer injections are therefore associated with a 
major reduction in health risks. Many studies have found a negative association between OST 
and injection drug use (Camacho et al., 1997; Dolan et al., 2003; Kwiatkowski and Booth, 
2001). This study contributes to the evidence showing that OST appears to reduce the health 
risks associated with injecting behaviour in NEP participants who are in OST.  
The level of polysubstance use was, however, high in this study, and there were no 
differences between OST users and the two other groups. Two other studies also found high 
levels of polysubstance use among comparable populations of NEP participants (Gervasoni et 
al., 2012; Kerr et al., 2005). This suggests that OST is not optimal in reducing polysubstance 
use and that, despite fewer non-fatal overdoses, there is a need for specific interventions to 
reduce health risks further.  
Harm to others caused by theft and drug dealing are important societal cost factors (Collins 
and Lapsley, 2008). Although drug dealing can have serious adverse consequences for the 
general community concerning issues such as increased drug availability, violence among 
market participants and societal costs for law enforcement, it is generally assumed to be less 
harmful than theft (McCollister et al., 2010). Theft often imposes substantial harms and costs 
to third-parties (García-Altés et al., 2002). OST has been found to reduce criminal activities in 
patients (Bukten et al., 2012). In the current study the negative association between OST and 
theft was no longer significant in the adjusted model, whereas the association between OST 
and drug dealing remained significant in the adjusted model. In a comparable study from 
Switzerland they also found a negative association between OST and illegal activities, but, as 
in this study, the findings were no longer significant after adjusting for other variables 
(Gervasoni et al., 2012). The lack of statistically significant results could be due to an 
insufficient number of subjects rather than a lack of real differences. On the other hand, it 
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could also indicate that NEP users who are currently in OST differ from OST users in general 
in that the association between OST and theft is weaker. 
4.2 Strengths and limitations 
The cross-sectional design limits casual inference. Furthermore, as with all studies that use 
self-reported data, possible weaknesses of this study include selection bias, recall bias, under- 
and over-reporting, and imprecise estimation of illegal activities. NEP participants may under-
report their drug use due the social stigma attached to that behaviour and those currently in 
OST may further under-report because of their patient status. However, OST status is one of 
the final questions in the questionnaire, which may reduce this likelihood of under-reporting. 
Also, anonymous interviews increase the risk of repeated observations across interview 
sessions. However, this potential source of bias was reduced as possible duplicates were 
removed as described in details in the Methods section. Additionally, it is not likely that an 
individual has been interviewed more than once within the same interview session. This 
means that if an individual should appear in another year the OST status and outcome variable 
will only be related to the previous four weeks for the specific interview. Furthermore, it can 
be shown that when the sample size is small relative to the population size (like in the present 
case), repeated observations will not significantly influence the results.  
The sample’s gender and age distribution is similar to what is assumed for IDUs in Norway 
(Bretteville-Jensen and Amundsen, 2006), and the high number of needles and syringes 
distributed annually suggests that a large proportion of the city’s IDUs are using the NEP 
facility in the city centre. People who inject drugs regularly are more likely to attend the NEP 
than those who inject less frequently, and consequently, the sample probably includes a higher 
proportion of the former population than the latter.  
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Importantly, it is likely that our data collection method allowed us to recruit IDUs who may 
not have been able to attend follow-up evaluations in long-term cohort studies. It is therefore 
possible that this study included a slightly different population than those usually assessed in 
cohort and treatment studies, and this enables a different view on the benefits of OST.  
4.3 Conclusions 
NEP participants who are currently in OST appear to have clear health benefits including 
fewer non-fatal overdoses, fewer injections and less heroin use. In addition those who are 
currently in OST appear to be associated with less criminal activity. Although those in OST 
had fewer non-fatal overdoses, the sustained high level of polysubstance use nevertheless 
poses a public health challenge as polysubstance use has been associated with an increased 
risk of overdoses (Kerr et al., 2007). It is therefore important that preventive and harm 
reduction strategies are developed in order to address this issue to reduce mortality and 
morbidity further in this population. Nevertheless, our findings suggest that there are large 
health benefits in providing OST also to those who continue to inject drugs while in 
treatment. 
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